<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04100330</url>
  </required_header>
  <id_info>
    <org_study_id>AV-299-19-207</org_study_id>
    <nct_id>NCT04100330</nct_id>
  </id_info>
  <brief_title>A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid Leukemia</brief_title>
  <acronym>CyFi2</acronym>
  <official_title>A Phase 2, Randomized, Open-Label, Multicenter Study of Ficlatuzumab in Combination With High-Dose Cytarabine (HiDAC) and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AVEO Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biodesix, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AVEO Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, randomized, open-label, multicenter study to evaluate the safety and
      efficacy of ficlatuzumab in combination with high-dose cytarabine (HiDAC) and HiDAC alone in
      subjects with relapsed or refractory acute myeloid leukemia.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Urgent shift among clinical sites toward efforts to combat COVID-19 pandemic;impacted
    feasibility of completing study within shelf-life of current IP supply
  </why_stopped>
  <start_date type="Anticipated">January 31, 2020</start_date>
  <completion_date type="Actual">March 27, 2020</completion_date>
  <primary_completion_date type="Actual">March 27, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Approximately 13 months (through study treatment completion)</time_frame>
    <description>To estimate the overall response rate (ORR) (complete remission [CR] + CR with incomplete hematologic recovery [CRi]) of ficlatuzumab in combination with high-dose cytarabine (HiDAC) and HiDAC alone in adults with relapsed or refractory acute myeloid leukemia (AML)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v5.0</measure>
    <time_frame>Approximately 14 months (through 30 days after the last subject completes treatment)</time_frame>
    <description>To evaluate the safety and tolerability of ficlatuzumab when administered with HiDAC and HiDAC alone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>For up to one year after the end of study treatment</time_frame>
    <description>To estimate the overall survival (OS) rate of ficlatuzumab in combination with HiDAC and HiDAC alone in adults with relapsed or refractory AML</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-Free Survival (DFS)</measure>
    <time_frame>For up to one year after the end of study treatment</time_frame>
    <description>To estimate the disease-free survival (DFS) rate of ficlatuzumab in combination with HiDAC and HiDAC alone in subjects achieving CR</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Ficlatuzumab with HiDAC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ficlatuzumab 20 mg/kg intravenously (IV) on Days 1 and 15 in combination with cytarabine 2 g/m2 IV per day on Days 2 through 7. Up to two additional doses can be administered - on Day 29, or on Days 29 and 43, if prolonged myelosuppression is experienced.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HiDAC alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cytarabine 2 g/m2 IV per day on Days 1 through 6</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ficlatuzumab</intervention_name>
    <description>Ficlatuzumab is a selective recombinant humanized hepatocyte growth factor (HGF) inhibitory immunoglobulin G subclass 1 monoclonal antibody which blocks the MET tyrosine kinase receptor.</description>
    <arm_group_label>Ficlatuzumab with HiDAC</arm_group_label>
    <other_name>AV-299</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Cytarabine is a chemotherapy agent. Chemotherapy agents are medications that kill cancer cells.</description>
    <arm_group_label>Ficlatuzumab with HiDAC</arm_group_label>
    <arm_group_label>HiDAC alone</arm_group_label>
    <other_name>Ara-C</other_name>
    <other_name>Arabinosylcytosine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of AML according to the WHO criteria, which defines relapsed or refractory
             to induction therapy as follows:

               1. First relapse within 12 months after date of first CR or CRi

               2. Persistent AML documented by bone marrow biopsy at least 29 days after Day 1 of
                  the first induction cycle of cytotoxic chemotherapy

               3. Hypercellular bone marrow with greater than 20% cellularity and 10% blasts at
                  least 14 days after the first induction cycle Day 1

          2. Age ≥18 years

          3. Prior induction therapy, consisting of no more than 2 cycles of cytotoxic chemotherapy
             with at least one of the cycles consisting of anthracycline and cytarabine with
             reasonable schedule/dose intensity according to the discretion of the Investigator

          4. Histologically confirmed AML by hematopathology review performed within 4 weeks of
             study entry. Secondary AML due to progression of myelodysplastic syndrome or
             myeloproliferative neoplasms is acceptable for inclusion.

          5. Prior treatment for myelodysplastic syndrome or myeloproliferative neoplasm with
             hypomethylating agent or targeted agent is acceptable for inclusion

          6. Ejection fraction ≥40% by echocardiogram or multigated acquisition (MUGA) scan

          7. Cytoreduction therapy with leukapheresis or hydroxyurea is allowed

          8. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

          9. Clinical laboratory values meeting the following criteria before Day 1 (Cycle 1, Day
             1):

               1. An estimated glomerular filtration rate of ≥ 60mL/min based on Cockcroft-Gault
                  equation calculated using serum creatinine levels

               2. Total bilirubin ≤2.0 mg/dL (≤3.0 mg/dL for subjects with known Gilbert's
                  syndrome)

               3. Aspartate aminotransferase (AST) or ALT ≤2.5 × ULN, unless thought to be due to
                  AML

               4. Activated partial thromboplastin time ≤1.5 × ULN and prothrombin
                  time/international normalized ratio (PT/INR) ≤1.5 × ULN if not on anticoagulation
                  therapy. Subjects receiving anticoagulation therapy with an agent such as
                  warfarin or low-molecular weight heparin may be allowed to participate with the
                  therapeutic range established before initiation of study treatment.

         10. For female subjects of childbearing potential, documentation of negative serum
             pregnancy test before randomization

         11. For female subjects of childbearing potential and male subjects whose sexual partners
             are of childbearing potential, agreement to use an effective method of contraception
             during the study and for at least 90 days after the last dose of ficlatuzumab.
             Effective birth control includes (a) intrauterine device plus 1 barrier method; (b)
             oral, implantable, or injectable contraceptive plus 1 barrier method; or (c) 2 barrier
             methods. Effective barrier methods are male or female condoms, diaphragms, and
             spermicides (creams or gels that contain a chemical to kill sperm).

         12. Ability to give written informed consent and comply with protocol requirements

        Exclusion Criteria:

          1. History of severe allergic or anaphylactic reactions or hypersensitivity to
             recombinant proteins or excipients in the investigational agent or cytarabine

          2. Acute promyelocytic leukemia (AML French-American-British classification M3)

          3. More than 2 cycles of prior induction therapy for AML

          4. Prior treatment with intermediate- or HiDAC (≥1 gm/m2)

          5. Allogeneic or autologous hematopoietic cell transplantation within 90 days of study
             entry

          6. Prior treatment with any other investigational drugs, biologics, or devices, within 4
             weeks before Day 1

          7. Active graft versus host disease or immunosuppression for prevention or treatment of
             graft versus host disease within 4 weeks of study entry

          8. Chemotherapy or radiation therapy within 1 week before study entry, other than
             hypomethylating agents or hydroxyurea used for cytoreduction

          9. Significant cardiovascular disease, including:

               1. Cardiac failure New York Heart Association class III or IV

               2. Myocardial infarction, severe or unstable angina within 6 months before Day 1

               3. History of serious ventricular arrhythmia (ie, ventricular tachycardia or
                  ventricular fibrillation)

         10. Significant thrombotic or embolic events within 3 months before Day 1 (significant
             thrombotic or embolic events include, but are not limited to, venous thromboembolism,
             stroke, or transient ischemic attack). Catheter-related thrombosis is not a cause for
             exclusion. Diagnosis of deep vein thrombosis or pulmonary embolism is allowed if it
             occurred &gt;3 months before Day 1 and anticoagulation therapy is completed before Day 1.

         11. Any other medical condition or psychiatric condition that, in the opinion of the
             Investigator, might interfere with the subject's participation in the trial or
             interfere with the interpretation of trial results

         12. History of prior/concurrent malignancy whose natural history or ongoing treatment is
             expected to interfere with the safety or efficacy assessment of the intervention

         13. Known seropositive or active HIV

         14. Active hepatitis B or C infection

         15. Uncontrolled systemic fungal, bacterial, or viral infections

         16. For female subjects, pregnant or breastfeeding

         17. Prior exposure to the investigational agent or anti-c-MET, or anti-HGF within 6 months
             before study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 12, 2019</study_first_submitted>
  <study_first_submitted_qc>September 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2019</study_first_posted>
  <last_update_submitted>March 27, 2020</last_update_submitted>
  <last_update_submitted_qc>March 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

